Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome;Uso de inmunoglobulina intravenosa en el tratamiento de necrólisis epidérmica tóxica y síndrome de Stevens-Johnson

Anales de Pediatria

Volumn 67, Issue 1, 2007, Pages 68-73

  Kuhn Cordova I ^a,b   Ramirez Bouchan D ^a   Gamboa Marrufo, J D ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b NONE   (Italy)

Author keywords

Intravenous immunoglobulin; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE; CETIRIZINE; CHLORAMPHENICOL; CHLORPHENIRAMINE; COTRIMOXAZOLE; DICLOXACILLIN; DIPHENHYDRAMINE; DIPYRONE; GLYCEROL; HYDROCORTISONE; IMMUNOGLOBULIN; LAMOTRIGINE; PARACETAMOL; PENICILLIN G; PHENYTOIN; RIBAVIRIN; SULFAMETHOXAZOLE; TALC; TOBRAMYCIN; ZINC OXIDE;

ALLOPATHY; ARTERIAL PRESSURE; ARTICLE; BLEPHARITIS; BLISTER; BREATHING RATE; CASE REPORT; CHICKENPOX; CHILD; DYSURIA; EPITHELIZATION; ERYTHEMA; FEMALE; FEVER; HEART RATE; HUMAN; HYPOPIGMENTATION; LABORATORY TEST; MALE; MIGRAINE; PAPULAR RASH; PHYSICAL EXAMINATION; PUS; SKIN DEFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TACHYPNEA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VOMITING;

EID: 34547623387     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13108083     Document Type: Article

References (20)

1. Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol. 1990;122:837-8.
2. Becker DS. Toxic epidermal necrolysis. Lancet. 1998;351:1417-20.
3. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-85.
4. Letko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Ann Allergy Asthma Immunol. 2005;94:419-36.
5. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 1997;24:726-9.
6. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134:710-4.
7. Halebian PH, Corder VJ, Madden MR, Finklestein JL, Shires GT. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204:503-12.
8. Esterly NB. Corticosteroids for erythema multiforme? Pediatr Dermatol. 1989;6:229-50.
9. Metry DW, Jung P, Levy ML. Use of intravenous inmunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: Seven cases and review of the literature. Pediatrics. 2003;112:1430-6.
10. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92-6.
11. Sotelo-Cruz N, Hurtado-Valenzuela J, Rascón-Alcantar A. Síndrome de Stevens-Johnson. Informe de 7 casos. Bol med Hosp Infant Mex. 2005;62:25-32.
12. Taylor JA, Grube B, Heimbach DM, Bergman AB. Toxic epidermal necrolysis A comprehensive approach. Multidisciplinary management in a burn center. Clin Pediatr. 1989;28:404-7.
13. Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics. 2001;108:1162-8.
14. Adzick NS, Kim SH, Bondoc CC, Quinby WC, Remensnyder JP. Management of toxic epidermal necrolysis in a patient burn center. Am J Dis Child. 1985;139:499-502.
15. Villada G, Roujeau J-C, Clérici T, Bourgault I, Revuz J. Immunopathology of toxic epidermal necrolysis. Arch Dermatol. 1992;128:50-3.
16. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4 + and CD8 + cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol. 1995;155:462-72.
17. Amato GM, Travia A, Ziino O. The use of intravenous high-dose immunoglobulins (IVIG) in a case of Stevens-Johnson syndrome. Pediatr Med Chir. 1992;14:555-6.
18. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3.
19. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory disease with intravenous immune globulin. N Engl J Med. 2001;345:747-55.
20. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, et al. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26-32.